Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New diabetes drug faces off against semaglutide in major trial

NCT ID NCT07064486

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 28 times

Summary

This study tests a new medicine called BGM0504 against a well-known drug, semaglutide, in people with type 2 diabetes. All participants take metformin and then receive either BGM0504 or semaglutide once a week. The main goal is to see which drug lowers blood sugar more after 24 weeks. The trial is for adults with stable weight and blood sugar levels between 7.5% and 11.0%.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES (T2DM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • RS Universitas Indonesia

    RECRUITING

    Depok, West Java, Indonesia

  • RSUP Fatmawati

    RECRUITING

    Jakarta, Indonesia

  • RSUP Persahabatan

    RECRUITING

    Jakarta, Indonesia

  • RSUPN Dr. Cipto Mangunkusumo

    RECRUITING

    Jakarta, Indonesia

Conditions

Explore the condition pages connected to this study.